S63 Use of NMR spectroscopy and nanospray mass spectrometry to characterise binding of lead compounds for drug design in α1-antitrypsin deficiency | Thorax

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Citation Tools

Spoken sessions

α1-Antitrypsin: what it tells us about COPD

S63 Use of NMR spectroscopy and nanospray mass spectrometry to characterise binding of lead compounds for drug design in α1-antitrypsin deficiency

Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Nyon M, Levy G, Kirkpatrick J, et al

S63 Use of NMR spectroscopy and nanospray mass spectrometry to characterise binding of lead compounds for drug design in α1-antitrypsin deficiency

Thorax 2010;65:A30.